Physician profile
Anna Taylor
NPI 1205569258
$5,826.39
in general payments reported to CMS, 2019-2025
20 companies · $4,270 in 2025
The $4,270 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $86.19 · 2024: $1,470 · 2025: $4,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,383 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,382.54 |
| Education | $443.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,151.42 | 2023-2025 | |
| Janssen Biotech, INC. | $826.76 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $655.20 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $429.14 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $376.64 | 2024-2025 | |
| Genzyme Corporation | $311.15 | 2024-2025 | |
| Galderma Laboratories, L.P. | $297.54 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $275.75 | 2024-2025 | Vtama, Nexplanon |
| Amgen INC. | $259.89 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $245.93 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $240.65 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $167.96 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $137.61 | 2024-2025 | |
| Pfizer INC. | $109.70 | 2025 | |
| Botanix Sb INC | $98.67 | 2025 | Sofdra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Incyte Corporation | $77.27 | 2025 | Opzelura, Opzelura |
| Biofrontera INC. | $43.34 | 2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $19.80 | 2023 | Valchlor |
| Verrica Pharmaceuticals INC. | $16.97 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.